Drug Trial Radar · NCT07940829
A Study of RSS0343 Tablets in Healthy Participants and in Participants With Mild or Moderate Renal Impairment
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Feb 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Reistone Biopharma Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single-center, single-dose, open-label study designed to evaluate the pharmacokinetic (PK) profile of RSS0343 tablets in healthy participants and in participants with mild or moderate renal impairment.
Conditions
- Non-cystic Fibrosis Bronchiectasis
- Chronic Sinusitis Without Nasal Polyps
- Chronic Obstructive Pulmonary Disease
Interventions
RSS0343 TabletDrug
RSS0343 tablet, oral.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The maximum plasma concentration (Cmax)Time frame: Day 1 - Day 12.
- The area under the blood drug concentration-time curve from Time 0 to the last quantifiable concentration time (AUC0-t)Time frame: Day 1 - Day 12.
- The area under the blood drug concentration-time curve from Time 0 to the extrapolated infinite time (AUC0-inf)Time frame: Day 1 - Day 12.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.